Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on advanced solid tumor treatments, has announced its participation in three major industry events this November. The company will be present at BIO-Europe in Stockholm (Nov 4-6, with virtual sessions Nov 12-13), where VP Tariq Imam will conduct one-on-one meetings. At the PEGS Europe Summit in Barcelona (Nov 5-7), CEO David J. Mazzo will present on Nov 5 at 3:20 p.m. CEST. Additionally, Dr. Mazzo will present at the LSX Inv€$tival showcase in London's Tobacco Dock on Nov 18 at 1:00 p.m. GMT.
Lisata Therapeutics (Nasdaq: LSTA), un'azienda farmaceutica in fase clinica focalizzata sui trattamenti per tumori solidi avanzati, ha annunciato la sua partecipazione a tre importanti eventi del settore questo novembre. L'azienda sarà presente al BIO-Europe a Stoccolma (dal 4 al 6 novembre, con sessioni virtuali il 12 e 13 novembre), dove il VP Tariq Imam condurrà incontri individuali. Al PEGS Europe Summit a Barcellona (dal 5 al 7 novembre), il CEO David J. Mazzo presenterà il 5 novembre alle 15:20 ora CEST. Inoltre, il Dr. Mazzo presenterà al LSX Inv€$tival showcase nel Tobacco Dock di Londra il 18 novembre alle 13:00 ora GMT.
Lisata Therapeutics (Nasdaq: LSTA), una compañía farmacéutica en etapa clínica enfocada en tratamientos avanzados para tumores sólidos, ha anunciado su participación en tres importantes eventos de la industria este noviembre. La empresa estará presente en BIO-Europe en Estocolmo (del 4 al 6 de noviembre, con sesiones virtuales el 12 y 13 de noviembre), donde el VP Tariq Imam llevará a cabo reuniones uno a uno. En el PEGS Europe Summit en Barcelona (del 5 al 7 de noviembre), el CEO David J. Mazzo presentará el 5 de noviembre a las 15:20 hora CEST. Además, el Dr. Mazzo presentará en el LSX Inv€$tival showcase en Tobacco Dock de Londres el 18 de noviembre a la 1:00 p.m. GMT.
리사타 테라퓨틱스 (Nasdaq: LSTA)는 고급 고형종양 치료에 주력하는 임상 단계 제약 회사로, 이번 11월에 세 가지 주요 산업 행사에 참여한다고 발표했습니다. 이 회사는 BIO-Europe에 참석할 예정이며, 스톡홀름에서 11월 4일부터 6일까지 열리고, 11월 12일과 13일에는 가상 세션이 있습니다. VP 타리크 이맘이 1:1 회의를 진행할 것입니다. PEGS 유럽 정상 회담은 바르셀로나에서 11월 5일부터 7일 동안 진행되며, CEO 데이비드 J. 마조는 11월 5일 오후 3:20 CEST에 발표를 할 예정입니다. 추가로, 마조 박사는 11월 18일 오후 1시 GMT에 런던의 타바코 독에서 열리는 LSX Inv€$tival 이벤트에서 발표할 것입니다.
Lisata Therapeutics (Nasdaq: LSTA), une entreprise pharmaceutique en phase clinique spécialisée dans les traitements avancés des tumeurs solides, a annoncé sa participation à trois événements majeurs de l'industrie ce mois de novembre. L'entreprise sera présente à BIO-Europe à Stockholm (du 4 au 6 novembre, avec des sessions virtuelles les 12 et 13 novembre), où le VP Tariq Imam mènera des réunions individuelles. Lors du PEGS Europe Summit à Barcelone (du 5 au 7 novembre), le CEO David J. Mazzo présentera le 5 novembre à 15h20 CEST. De plus, Dr. Mazzo fera une présentation lors de la LSX Inv€$tival showcase au Tobacco Dock de Londres le 18 novembre à 13h00 GMT.
Lisata Therapeutics (Nasdaq: LSTA), ein in der klinischen Phase befindliches Pharmaunternehmen, das sich auf fortgeschrittene Behandlungen für solide Tumoren konzentriert, hat seine Teilnahme an drei wichtigen Branchenereignissen im November angekündigt. Das Unternehmen wird beim BIO-Europe in Stockholm (vom 4. bis 6. November, mit virtuellen Sitzungen am 12. und 13. November) präsent sein, wo VP Tariq Imam Einzelgespräche führen wird. Auf dem PEGS Europe Summit in Barcelona (vom 5. bis 7. November) wird CEO David J. Mazzo am 5. November um 15:20 Uhr CEST präsentieren. Darüber hinaus wird Dr. Mazzo am LSX Inv€$tival showcase im Tobacco Dock in London am 18. November um 13:00 Uhr GMT präsentieren.
- None.
- None.
BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate at the following events in November:
BIO-Europe (November 4-6, 2024; Virtual: November 12-13, 2024)
Format: In-person/Virtual
Location: Stockholm, Sweden
Lisata representative: Tariq Imam, Vice President of Business Development and Operations and Corporate Counsel at Lisata
Mr. Imam will be participating in one-on-one meetings at this event. If interested in meeting, please send a meeting request through the online partnering platform. For more information on BIO-Europe and how to register, please click here or contact EBDcustomerservice@ebdgroup.com.
PEGS Europe Summit (November 5-7, 2024)
Format: In-person
Location: Barcelona, Spain
Presentation Date: Tuesday, November 5, 2024
Presentation Time: 3:20 p.m. CEST
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer at Lisata
For more information on PEGS Europe and how to register, please click here.
LSX Inv€$tival showcase 2024 (November 18, 2024)
Format: In-person
Location: Tobacco Dock, UK
Presentation Date: Monday, November 18, 2024
Presentation Time: 1:00 p.m. GMT
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
For more information on the LD Micro Main Event and how to register, please click here or contact steph@lsxleaders.com.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s internalizing RGD, or Arginylglycylaspartic acid, (iRGD) cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
FAQ
What events will Lisata Therapeutics (LSTA) attend in November 2024?
Who will represent Lisata Therapeutics (LSTA) at BIO-Europe 2024?
When will CEO David Mazzo present at PEGS Europe Summit 2024?
What is the date and time of Lisata's (LSTA) presentation at LSX Inv€$tival 2024?
